Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)

NCT03807843 | Completed Phase 2 Results DMC FDA Drug

• 2 other identifiers: V184-006MV-CHIK-206
• Study Type: interventional
• Target: 41
• Locations: 1 country
• Sites: 1

Brief Summary

Safety and immunogenicity of the investigational V184 chikungunya vaccine will be tested in participants with history of chikungunya infection. Initially 21 to 50 year old participants will be enrolled; after favorable review of safety data, participants aged 51 to 65 will be enrolled.

Conditions

Chikungunya Virus Infection

Outcome Measures

Primary Outcomes (3)

• Number of Participants With Solicited Adverse Events (AEs)

  An AE was defined as any untoward medical occurrence temporally associated with the use of the treatment that did not necessarily have a causal relationship with the treatment. "Solicited AEs" included fever, fatigue, headache, malaise, myalgia, nausea/vomiting, joint pain or injection site itching, pain/tenderness, erythema/redness or induration/swelling that occurred within 7 days of vaccination. The number of participants with solicited AEs following Vaccination 1 (Day 0) or Vaccination 2 (Day 28) were reported for each group.

  Up to 7 days after vaccination (up to Day 35)

• Number of Participants With Unsolicited AEs

  An AE was defined as any untoward medical occurrence temporally associated with the use of the treatment that did not necessarily have a causal relationship with the treatment. "Unsolicited AEs" were defined as events reported within 7 days after each vaccination and not defined as solicited AE, and all AEs reported more than 7 days after vaccination. The number of participants with unsolicited AEs were reported for each group.

  Up to Day 196

• Number of Participants With Solicited and Unsolicited AEs of Grade 2 or Higher According to the 2007 Toxicity Grading Scale for Healthy Adult Volunteers Enrolled in Preventive Vaccine Clinical Trials (2007)

  An AE was defined as any untoward medical occurrence temporally associated with the use of the treatment that did not necessarily have a causal relationship with the treatment. "Solicited AEs" included fever, fatigue, headache, malaise, myalgia, nausea/vomiting, joint pain or injection site itching, pain/tenderness, erythema/redness or induration/swelling that occurred within 7 days of vaccination. "Unsolicited AEs" were defined as events reported within 7 days after each vaccination and not defined as solicited AE, and all AEs reported more than 7 days after vaccination. AEs were graded by the investigator for severity as per the FDA Toxicity Grading Scale for Healthy Adults Enrolled in Vaccine Clinical Trials (2007), where Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=potentially life threatening. A higher grade indicates increased severity of AE. The number of participants with solicited and unsolicited AEs of grade 2 (moderate) or higher were reported for each group.

  Up to Day 196

Secondary Outcomes (1)

• Geometric Mean Fold Rise (GMFR) of Serum Neutralizing Antibodies (nAb) to V184 Over Time

  Days 0, 28, 56, and 196

Study Arms (2)

V184

EXPERIMENTAL

Participants will receive 2 vaccinations with V184 administered via intramuscular (IM) injection at 5 × 10\^5 Tissue Culture Infectious Dose (TCID50) per dose on Days 0 and 28.

Biological: V184

Placebo

PLACEBO COMPARATOR

Participants will receive 2 injections of sterile physiological saline administered via IM injection on Days 0 and 28.

Other: Placebo

Interventions

V184 BIOLOGICAL

Recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. Liquid frozen, life attenuated, measles vectored V184 vaccine administered via IM injection at 5 × 10\^5 TCID50 (+/- 0.5 log) per dose.

Also known as: MV-CHIK, MV-CHIK vaccine, MV-CHIK/DP (drug product)

V184

Placebo OTHER

Sterile physiological saline for IM injection

Placebo

Eligibility Criteria

• Age: 21 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Previous infection with chikungunya as verified by a serum immunoassay.
• Able to provide informed consent.
• Available and accessible for the duration of the trial.
• Able and willing to comply with all requirements of the study.
• For women of childbearing potential, willing to practice adequate contraception for the duration of the study.
• Medical history and physical examination findings are considered normal or not clinically significant in the opinion of the Investigator, which includes resolution of any arthralgias that may have occurred during prior chikungunya infection, as well as the absence of synovitis.
• Laboratory values are considered normal or not clinically significant in the opinion of the Investigator. If laboratory screening tests are out of the normal reference range and of potential clinical significance, the test(s) may be repeated up to 2 times (a total of 3 per screening evaluation) at the discretion of the Investigator, and the repeat values and their potential clinical significance will be used to determine eligibility.
• History of immunity to measles. For persons born after 1957, this will be established by a history of compliance with vaccination policies that included measles vaccination or known vaccination as an adult at least one month before they are randomized. Volunteers born before 1957 will be presumed to have immunity to measles based on natural exposure in accordance with US Centers for Disease Control and Prevention (CDC) guidelines \[McLean 2013\].

You may not qualify if:

• Taking medication or other treatment for unresolved symptoms attributed to a previous chikungunya virus infection.
• Prior receipt of any investigational chikungunya or other alphavirus vaccine. To date, no alphavirus vaccines have been commercially available in the United States.
• Recent infection:
• self-limited upper respiratory infections until afebrile without medication for \>1 week;
• chikungunya unless/until asymptomatic (other than mild subjective symptoms not requiring treatment) for \>3 months;
• non-recurrent upper respiratory or urinary tract infections successfully treated with antibiotics, until asymptomatic for 1 month after full antibiotic course has been completed.
• History of an acute allergic or anaphylactic reaction to any vaccine.
• History of an immunosuppressive disorder (such as human immunodeficiency virus \[HIV\] infection, Common Variable Immune Deficiency), chronic infection (such as chronic hepatitis B or C), autoimmune disease (such as rheumatoid arthritis, systemic lupus erythematosus (SLE), autoimmune thyroid disease), or any medical condition that, in the opinion of the Investigator, could lead to an atypical immune response to the vaccine.
• History of moderate or severe non-traumatic arthritis or arthralgia within 3 months of the Screening Visit.
• Recent (within 30 days), current or anticipated use of any immunosuppressive or immune modifying medication including corticosteroids (excluding nasal, ophthalmic, and other topical preparations).
• Other vaccination or planned vaccination within 4 weeks of either study dose (seasonal influenza vaccine excepted).
• Receipt or planned receipt of blood products including immunoglobulins within 120 days of the Screening Visit.
• Pregnant or lactating or planning pregnancy during the trial.
• Known alcohol or other substance abuse that in the opinion of the Investigator affects the ability or willingness of the participant to understand and comply with the study protocol.
• Participation in another clinical study within the past 30 days in which the participant was exposed to an investigational product (pharmaceutical product or placebo or device) or planned participation in another interventional clinical study while participating in this study.

Sponsors & Collaborators

• Themis Bioscience GmbH: lead
• Walter Reed Army Institute of Research (WRAIR): collaborator

Study Sites (1)

San Juan Hospital, Research Unit

San Juan, Puert Rico, 00935, Puerto Rico

Location

MeSH Terms

Conditions

Chikungunya Fever

Interventions

Dosage Forms

Condition Hierarchy (Ancestors)

Alphavirus Infections; Arbovirus Infections; Vector Borne Diseases; Infections; Mosquito-Borne Diseases; Virus Diseases; Togaviridae Infections; RNA Virus Infections

Intervention Hierarchy (Ancestors)

Pharmaceutical Preparations; Technology, Pharmaceutical; Investigative Techniques

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

1-800-672-6372

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Study medication is available as liquid frozen vaccine product or saline for injection (placebo). The actual study injections will be forwarded to the investigator (injector) in a blinded fashion (injection ready syringes containing either vaccine or placebo).
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Placebo-controlled, randomized, double-blinded, interventional, safety study

Study Record Dates

• First Submitted: January 15, 2019
• First Posted: January 17, 2019
• Study Start: July 16, 2019
• Primary Completion: May 13, 2021
• Study Completion: May 13, 2021
• Last Updated: September 8, 2022
• Results First Posted: May 16, 2022

Record last verified: 2022-09

Data Sharing

• IPD Sharing: Will share

Locations

PR (1)